Polyene phosphatidylcholine clinical trials
Also written AYP-101.
How each study uses polyene phosphatidylcholine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
AMIpharm Co., Ltd. (4) · Sichuan Haisco Pharmaceutical Group Co., Ltd (1) · Jun Cheng (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Hypolipidemic Agents source
Studies
Open first, then newest update. How each study uses polyene phosphatidylcholine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy SubjectsCompletedPhase 1AMIpharm Co., Ltd.NCT05476094Written as Polyene Phosphatidylcholine
- Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin AreaCompletedPhase 3AMIpharm Co., Ltd.NCT06256445Written as Polyene Phosphatidylcholine
- Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin AreaCompletedPhase 2AMIpharm Co., Ltd.NCT05266729Written as Polyene Phosphatidylcholine
- Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental FatCompletedPhase 2AMIpharm Co., Ltd.NCT03982225Written as Polyene phosphatidylcholine injection
- Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver InjuryCompletedPhase 4Sichuan Haisco Pharmaceutical Group Co., LtdNCT04595916Written as Polyene phosphatidylcholine injection 930 mg QD
- Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B PatientsStatus unknownPhase 4Jun ChengNCT01436539Written as Adefovir Dipivoxil and polyene phosphatidylcholine
Given beside what is tested · 1 — polyene phosphatidylcholine is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with polyene phosphatidylcholine
Codes
What other systems call polyene phosphatidylcholine · ClinicalTrials.gg INT002893
- MeSH (NLM) C029449polyene phosphatidylcholineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C029449 | polyene phosphatidylcholine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.